European Industry Seeks Action On Shortages
Medicines For Europe Asks New European Commission For ‘Policy Response’
Medicines For Europe has called on EU leaders to take action on the issue of medicine shortages, urging the new European Commission to prioritize shortage prevention in its first 100 days.
You may also be interested in...
Christoph Stoller, Teva’s general manager for Germany and Austria, has just been announced as president of European off-patent industry association Medicines for Europe with a two-year mandate. In an exclusive interview, he sets out the organization’s immediate priorities.
Alvogen’s newly created B2B unit, Adalvo, has partnered with AmbioPharm for the co-development and licensing for the commercialization of several complex pharmaceutical products, including difficult-to-make peptides, in key global markets.
Kodak’s new pharmaceutical unit receives a $765m loan from the US International Development Finance Corporation, through President Trump’s Defense Production Act, to produce critical pharma components that are essential but have lapsed into chronic national shortage, as defined by the FDA.